Trial Profile
A Phase 2, Open-Label, Multi-Center Trial of Mavorixafor in Patients With WHIM Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Mavorixafor (Primary)
- Indications WHIM syndrome
- Focus Adverse reactions; Proof of concept
- Sponsors X4 Pharmaceuticals
- 05 Sep 2023 Status changed from active, no longer recruiting to completed.
- 14 Dec 2021 Results of the long-term extension study were presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 04 Nov 2021 According to a X4 Pharmaceuticals media release, data will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting.